Castor EDC Alternatives: How to Compare Them in 2026

The right alternative to your current EDC depends on what it leaves to a second system or to a vendor service. Datacapt fits CROs and sponsors in pharma, biotech, medical devices, consumer health and academic research that want EDC, ePRO, eConsent, randomization, trial supply and televisits on one patient record, an AI agent that builds the study with them, and unlimited users on every plan.

You are reading this because Castor is on your shortlist, or because a contract renewal made you look again. This page compares Castor with five alternatives on who builds the study, which modules share the same record, and which studies each platform is built for, then sets Datacapt and Castor side by side.

How do the main Castor EDC alternatives compare?

Five platforms come up when teams look beyond Castor: Datacapt, Medrio, OpenClinica, REDCap and Viedoc. They split on build model, module coverage and target study. Each cell below restates what the vendor publishes on its own product pages, checked in September 2026, with the platforms in alphabetical order.

| Platform | Who builds the study | Modules published | Built for |

| Castor | Your team, in a no-code form builder, with Castor Academy courses and certification. Castor's professional services can build it for you. | EDC and CDMS, eCOA and ePRO, eConsent, randomization, AI data extraction from source documents, registry and post-market products | Academic research, biotech, medical device sponsors and CROs. Castor states that low-complexity studies launch in 3 to 4 weeks. |

| Datacapt | Your clinical team, in a visual builder, without programming | EDC, ePRO, eConsent, randomization, medical coding, trial supply, televisits, Site CTMS, Datacapt AI with an MCP server | CROs, pharma and biotech sponsors, medical device teams, consumer health brands and academic institutes, from Phase I to IV, real-world evidence and patient registries |

| Medrio | Your team, with spreadsheet-style logic instead of scripting | EDC, eCOA and ePRO, eConsent, RTSM, CTMS, eTMF | Early-phase research and CROs running fast development programs |

| OpenClinica | Your team, with drag-and-drop tools and templated CRFs, or OpenClinica's team, which offers a study build | EDC, eConsent, eCOA, randomization, EHR-to-EDC, reporting, patient recruitment | Academic research organizations, investigator-initiated studies, sponsors without an internal build team |

| REDCap | Your institution's team, on an installation your institution hosts | Data capture and surveys, installed and maintained by each member institution | Academic teams with internal IT capacity and investigator-initiated studies |

| Viedoc | Your team, after Viedoc Study Build Certification, or Viedoc's study build service | EDC, ePRO, televisits, randomization and trial supply, medical coding, eTMF | Mid-size sponsors and CROs running studies with stable protocols across several geographies |

For the full market view, with thirteen platforms grouped by study type, see our comparison of 13 EDC platforms.

How does Datacapt compare with Castor?

Datacapt and Castor both let your own team build the study without programming. They part ways on what sits on the same patient record, how fast a study goes live, and what drives the price. Each cell restates what the two vendors publish, checked in September 2026.

| Criterion | Castor | Datacapt |

| Who builds the study | Your team in a no-code form builder, with Castor Academy courses and certification, or Castor's professional services | Your clinical team in a visual builder, without programming, with a study build of 4 days |

| Time to go live | 3 to 4 weeks for a low-complexity study, as Castor states | 1 to 4 weeks per new study |

| Modules on one record | EDC and CDMS, eCOA and ePRO, eConsent, randomization | EDC, ePRO, eConsent, randomization, medical coding, trial supply, televisits |

| AI | AI data extraction from source documents, which a person accepts or rejects | Datacapt AI builds the study, reviews data as it arrives and watches your sites. It writes in draft only, never on a live study, and you can connect your own model over Datacapt's MCP server |

| Trial supply and site operations | Not listed on Castor's product pages as of September 2026 | Trial supply management and a Site CTMS on the same platform |

| Price | Tailored proposal after a call and a protocol review | One price per study or one annual licence, unlimited users on every plan, no implementation fee |

| EU data hosting | Certified servers in supported regions | Your choice of AWS regions or 3DS Outscale, a French sovereign cloud qualified SecNumCloud by ANSSI and certified HDS. Datacapt is the only platform in our 13-platform comparison that publishes SecNumCloud hosting |

You see the gap in the trial supply row. If your study dispenses blinded kits, or your sites need scheduling and patient payments, Datacapt keeps those tasks on the record that holds the clinical data, with no second system to reconcile.

What does Datacapt bring as an alternative?

Datacapt gives your team a study it builds and changes itself, every module on one patient record, and a price that does not grow with the user list. The figures below come from Datacapt's product and pricing pages.

• Study build in 4 days, first patient in during week one, as the Datacapt EDC product page states, and a time to go live of 1 to 4 weeks per new study.
• One patient record across EDC, ePRO, eConsent, randomization, medical coding, trial supply and televisits, with the Site CTMS on the same platform.
• Datacapt AI builds the study from the schedule of assessments, reviews data as it arrives and watches your sites. It runs on your permissions, writes to your audit trail and works in draft only, never on a live study. Your team can use the built-in assistant or connect its own model over MCP.
• Mid-study form changes by your own team, with no vendor ticket.
• One price per study or one annual licence, with unlimited users on every plan, no implementation fee, a validation package included, and migration from another EDC handled by the Datacapt team, as the pricing page sets out.
• Your choice of hosting: 3DS Outscale, a French sovereign cloud qualified SecNumCloud by ANSSI and certified HDS, or AWS regions for sponsors who need them, as the security page sets out.

Zurko Research, a CRO, runs more than 300 studies a year on Datacapt and completes its studies 45% faster, according to its customer story.

[[cta]]

What should you compare when you look beyond Castor?

Compare the platforms on your next study. Four questions separate the options faster than a demo script: which modules live on the same patient record, who builds and changes the study, what happens to the data when the protocol moves, and what the price covers over the real duration of the study.

Which modules share the patient record

Ask each vendor to show, in a live demo, every module your protocol needs working on one patient record. For each task that sits in a second system, ask who reconciles the data and how often.

Who builds the study, and after what training

Every platform in this comparison lets your team build, and several also sell a build service. Ask how long your coordinator needs before building alone, whether a certification comes first, and who makes the change when a site asks for a new field in week six.

What happens to collected data when the protocol changes

A Tufts CSDD study of 950 protocols found that 76% undergo at least one amendment. Ask each vendor to walk through a past amendment of yours: who edits the form, how it reaches the sites, and whether the records entered under the previous version stay in one dataset.

What the price covers

Ask each vendor which unit drives its price, study, module or user, then ask for the price of your real study over its real duration, with every user your sponsors and sites will add. Check whether implementation, validation and migration come on top. Datacapt charges no implementation fee and includes the validation package and migration in its price.

How do you move a study off Castor?

Move at a study boundary when you can. A new study starts on the new platform while running studies finish where they began, which keeps each dataset in one system and avoids a mid-study revalidation. When a running study has to move, plan five steps. Datacapt's pricing includes migration from another EDC, handled by the Datacapt team.

1. Export the data, the audit trail and the study definition from the current platform.
2. Map each form, field and code list to the new structure, with your data manager.
3. Rebuild and test the study, then run user acceptance testing on the migrated records.
4. Reconcile record counts and key values between the two systems before sites switch.
5. Retrain sites on the new screens and archive the old system under your retention rules.

Our method article covers the evaluation sequence in more depth: how to choose an EDC for your clinical trial.

When is Datacapt not the right choice?

Datacapt suits teams that want to run the study build in-house and keep every module on one record. Four situations call for a different platform:

• Your sponsor mandates its own EDC. Large sponsors standardize on one platform across their programs, and the CRO runs the study where the sponsor decides.
• You run ultra-large, multi-program pharma standardization. Datacapt has a smaller global footprint than long-established enterprise vendors.
• You need a portfolio-level CTMS. Datacapt includes a Site CTMS for site operations. Contract, budget and resource management across a portfolio call for a dedicated CTMS.
• Your study starts from paper records and EHR exports. Castor sells an AI layer that reads source documents and proposes values for the eCRF, which a person accepts or rejects. Chart reviews and registries built on existing records gain most from it.

An EDC alternative earns its place on the second study more than on the first. Test the platform on the study you run next: the amendment you know is coming, the kits you will dispense, the users your sponsor will add. The answer tells you whether to switch now, at the next study, or not at all.